Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 204

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 204
---
center'>ARTICLE 1—DEFINITIONS</div>

1.1 “Licensed Product”
shall mean a drug product containing as an active agent 3aisopropyl-2-methyl-6-propyl-3a,8b-dihydro-1H-cyclopenta[b]benzofuran-8-ol or
a pharmaceutically acceptable salt, ester or ether thereof (“T-55”), and/or 8-hydroxy-3aisopropyl-2-methyl-6-propyl-3a,8b-dihydro-1H-cyclopenta[b]benzofuran-7-carboxylic
acid or a pharmaceutically acceptable salt, ester or ether thereof (“M308”).

1.2 “Patent Rights”
shall mean the patent applications listed on the attached Schedule A and all patents, continuations, continuations-in-part, divisionals,
reissues, substitutes, and reexamination certificates claiming priority thereto or issuing therefrom.

1.3 “Licensed Territory”
shall mean the United States and its territories and possessions, Canada and Mexico.

1.4 “Sublicensee”
shall mean any entity, whether a partnership, firm, company, corporation or otherwise to which Licensee grants a sublicense under the
Patent Rights.

1.5 “Net Sales Price”
shall mean the invoice price for Licensed Products sold in arm’s length sales or commercial transactions to a third party by Licensee,
its affiliates, or any third party which acquired ownership of any Licensed Product from Licensee, less deductions for taxes, duties,
and shipping charges separately stated on the invoice.

1.6 “Revenue” shall
mean any and all revenue or other consideration received for a Licensed Product, including but not limited to, revenue or royalties from
sales of Licensed Products, upfront revenue, milestone revenue, royalty income (e.g., running royalty or minimum royalty), license
fees, and the market value at the time of transfer of all non-monetary consideration such as in-kind contribution valued in money in the
country of disposition.

1.7 “Valid Claim”
shall mean a claim in an unexpired Letters Patent under the Patent Rights which has not been held invalid or unenforceable by a court
or tribunal of competent jurisdiction from which no further appeal can be taken or has been taken within the required time period.

1.8 “Field of Use”
shall mean therapeutic treatments and other medical or health uses in humans and preclinical